Baudax Bio Past Earnings Performance
Past criteria checks 0/6
Baudax Bio's earnings have been declining at an average annual rate of -562.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 217.3% per year.
Key information
-562.2%
Earnings growth rate
-118.5%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 217.3% |
Return on equity | n/a |
Net Margin | -4,665.2% |
Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Baudax Bio stock down after pricing $6.2M equity offering
Aug 30Baudax Bio to get US patent linked to pain drug Anjeso
Aug 22Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M
Aug 11Cosette Pharmaceuticals appoints Rick Casten as CFO
Jul 06Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds
Sep 09A First Look At Baudax Bio
May 30Baudax Bio EPS misses by $0.08, misses on revenue
May 05Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty
Apr 26Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?
Feb 17Baudax Bio EPS of $0.62
Nov 09Baudax Bio: Why I'm Catching This Falling Knife
Nov 03Revenue & Expenses Breakdown
How Baudax Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 1 | -59 | 19 | 8 |
30 Jun 23 | 1 | -61 | 18 | 7 |
31 Mar 23 | 1 | -58 | 19 | 6 |
31 Dec 22 | 1 | -59 | 24 | 4 |
30 Sep 22 | 0 | 13 | 24 | 3 |
30 Jun 22 | 1 | 0 | 32 | 3 |
31 Mar 22 | 1 | -11 | 40 | 3 |
31 Dec 21 | 1 | -20 | 45 | 3 |
30 Sep 21 | 1 | -66 | 44 | 6 |
30 Jun 21 | 1 | -38 | 47 | 7 |
31 Mar 21 | 1 | -53 | 47 | 7 |
31 Dec 20 | 0 | -76 | 43 | 9 |
30 Sep 20 | 0 | -66 | 38 | 7 |
30 Jun 20 | 0 | -88 | 29 | 8 |
31 Mar 20 | 0 | -69 | 21 | 11 |
31 Dec 19 | 0 | -33 | 23 | 17 |
30 Sep 19 | 0 | -42 | 23 | 26 |
30 Jun 19 | 0 | -51 | 23 | 34 |
31 Mar 19 | 0 | -61 | 31 | 38 |
31 Dec 18 | 0 | -74 | 29 | 36 |
Quality Earnings: BXRX.Q is currently unprofitable.
Growing Profit Margin: BXRX.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BXRX.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BXRX.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BXRX.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: BXRX.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/25 14:52 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2023/09/30 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Baudax Bio, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Esther Lannie Hong | Janney Montgomery Scott LLC |
Jason Butler | JMP Securities |
Gregory Aurand | NOBLE Capital Markets, Inc. |